ClinicalTrials.Veeva

Menu

Swalqol in Primary Hyperparathyroidism

U

Uşak University

Status

Completed

Conditions

Hyperparathyroidism

Treatments

Procedure: parathyroidectomy

Study type

Observational

Funder types

Other

Identifiers

NCT03968510
pthswalqol

Details and patient eligibility

About

Swallow related quality of life before and after parathyroidectomy will be evaluated in patients with primary hyperparathyridism.

Full description

Patients who will undergone parathyroidectomy for primary hyperparathyroidism will be included in the study. Swal-Qol and Sf-36 forms will be used for evaluation of quality of life before and 1 month after the surgery. The change in the quality of life and swallowing related quality of life will be evaluated.

Enrollment

150 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • no diagnosis of Alzheimers disease
  • must be able to swallow tablets Planned operation for primary hyperparathyroidism

Exclusion criteria

  • secondary or tertiary hyperparathyroidism
  • insulin dependent diabetes
  • thyroid disease

Trial design

150 participants in 1 patient group

parathyroidectomy cases
Description:
patients who will be operated for primary hyperparathyroidism
Treatment:
Procedure: parathyroidectomy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems